36 filings
Page 2 of 2
8-K
gj9jyp2s4u5u7ota7
31 Mar 23
Tscan Therapeutics Announces Ceo Transition
8:57am
8-K
hq38nd192zgatr 51vg
8 Mar 23
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
7:15am
8-K
5jnl4v b6igpqai
23 Jan 23
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
7:06am
8-K
dg67fl2
9 Nov 22
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:06am
8-K
k5bbfi34ff3xq
12 Sep 22
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures
7:51am
8-K
5v4p317h n35domp
10 Aug 22
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
12:00am
8-K
gas7k lxpw0
7 Jul 22
Departure of Directors or Certain Officers
7:11am
8-K
wzosnung 2rjybv0ral
3 Jun 22
Departure of Directors or Certain Officers
4:03pm
8-K
h43bubr8
31 May 22
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies
7:07am
8-K
bzwqorp4n vo5
9 May 22
TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones
7:08am
8-K
2dq7qgm saw4
9 Mar 22
TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities
7:13am
8-K
yf2nd7
24 Jan 22
TScan Therapeutics Announces FDA Clearance of Investigational New Drug
7:31am
8-K
d822t 1ut
2 Dec 21
Entry into a Material Definitive Agreement
7:31am
8-K
7ujaxr qwjaa5s96j
10 Nov 21
TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
7:02am
8-K
iv2zzpp fmknm
19 Aug 21
TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
7:15am
8-K
11wk6jbzlfzcojiw1mc
20 Jul 21
Departure of Directors or Certain Officers
4:36pm